Abstract Charcot-Marie-Tooth (CMT) disease is the most common inherited peripheral neuropathy characterized by progressive distal muscle weakness and atrophy with decreased or absent tendon reflexes. Mutations in LRSAM1 have been identified to cause CMT disease type 2P. We report a novel LRSAM1 mutation c.2021-2024del (p.E674VfsX11) in a Chinese autosomal dominant CMT disease type 2 family. The phenotype was characterized by late onset and mild sensory impairment. Electrophysiological findings showed normal or mildly to moderately reduced motor and sensory nerve conduction velocities in lower and upper limb nerves.
Introduction
Charcot-Marie-Tooth (CMT) disease is the most common inherited peripheral neuropathy. Based on electrophysiological and pathological findings, CMT can be divided into two forms: CMT type 1, the demyelinating type and CMT type 2, the axonal type. CMT is highly clinically and genetically heterogeneous, and mutations have been reported in at least 80 genes (Rossor et al., 2016; Pareyson et al., 2017) . In 2010, a mutation in LRSAM1 was found to cause CMT disease type 2P (Guernsey et al., 2010) . We report a novel LRSAM1 mutation in a Chinese family with autosomal dominant (AD) CMT disease type 2 and the clinical and electrophysiological features of the patients in this family.
Methods Subjects
This is a three-generation family with autosomal dominantly inherited CMT disease. All were of Han nationality. Standard motor and sensory nerve conduction studies were performed for all available family members.
Mutation analysis
Informed consent was obtained, and genomic DNA of blood cells was extracted from all consenting participants using a Genomic-tip kit (QIAGEN, Hilden, Germany) . Whole exome sequencing of the proband was performed by Axeq Technologies (RayLee Biotech, Shanghai, China) using Agilent SureSelect v6 reagents for capturing exons and Illumina HiSeq X Ten platform for sequencing. The specific mutation in LRSAM1 was confirmed by Sanger sequencing both the forward and reverse strands in all participants.
Results

Clinical information
There were six patients, including two deceased individuals (Fig. 1A) . The four living patients were all males (patient II:4, II:8, III:1, and III:4). The initial symptoms in all were difficulty in walking caused by slowly progressive weakness of the lower limbs. Atrophy was present in the distal parts of the lower limbs in patient III:1. Tendon reflexes were depressed or absent, with mild stocking sensory loss to pricking pain or vibration in the feet. Talipes cavus deformity was observed in patient II:4. There was no clawhand deformity. Other symptoms, including numbness and tingling in the feet were present in all four living patients. There was no cranial nerve involvement and no cerebellar or pyramidal signs. The mean ± SD age of onset was 42 ± 7.4 years. The duration of the disease was a mean ± SD of 10 ± 4.4 years. Patient II:4 required a walking stick after 7 years after the onset. The other three patients were able to walk alone but slowly. The symptoms and signs of the four living patients are summarized in Table 1 in detail. Nerve conduction studies showed mildly to moderately diminished motor nerve conduction velocity (NCV) in lower limb nerves but normal or slightly reduced MNCVs in upper limb nerves in three patients (II:4, II:8 and III:1). Sensory NCVs of median, ulnar, and sural nerves were reduced in two patients (II:4 and III:1). Patient III:4 showed normal NCVs. In all four patients, compound muscle action potential (CMAP) was normal in the upper limb nerves but reduced with varying degrees in lower limb nerves. Sensory nerve action potential (SNAP) amplitudes were mildly to severely reduced. Distal motor latencies were normal or mildly prolonged. The electrophysiological features of the four patients are summarized in Table 2 . According to the clinical and electrophysiological manifestations, all the patients were diagnosed as having CMT type 2.
Mutation analysis
By sequencing, we identified a single heterozygous mutation c.2021-2024del (p. E674VfsX11) in LRSAM1 in this family (Figs. 1B and 1C) . The mutation was detected in four symptomatic individuals and was absent in family members II:1 and II:3 and 200 normal chromosomes. It was also not present in the 1,000 Genomes Project database or the ESP6500 data set of the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (consisting of 4,300 exomes from European-Americans and 2,203 from African-American individuals).
Discussion
In the present study, clinical and electrophysiological features of all patients are typical of CMT disease type 2, including distal weakness beginning in the lower limbs, depressed or absent tendon reflexes, and mild sensory disturbance. Atrophy in the distal parts of the lower limbs and pes cavus were seen in one patient respectively. Electrophysiological studies were compatible with CMT disease type 2. In this family, the disorder usually has a late onset; individuals are mildly to moderately affected; and the course is very slow, with very late functional impairment.
Based upon our analysis, a novel mutation c.2021-2024del (p.E674VfsX11) was identified in exon 24 of LRSAM1 in this AD CMT disease type 2 Chinese family. The mutation results in an E674-to-V substitution and a concomitant frameshift maybe occur that introduces a stop codon 9 amino acids further down the new reading frame and is predicted to result in a protein that is 40 amino acids shorter than the normal protein. This novel mutation was predicted to be deleterious by SIFT and Polyphen analysis.
To date, eight pathogenic variants in LRSAM1 have been identified to cause CMT disease type 2P (Table 3 ; Guernsey et al., 2010; Weterman et al., 2012; Nicolaou et al., 2013; Engeholm et al., 2014; Hu et al., 2016; Peeters et al., 2016; Hakonen et al., 2017) . Recently, Hakonen et al. 2017 screened 575 CMT patients and identified a novel mutation (c.2120C > T, p.Pro707Leu), suggesting the frequency of a LRSAM1 mutation in CMT families is rare.
LRSAM1 protein is a RING-finger E3 ubiquitin ligase highly expressed in human fetal spinal cord, sensory ganglia and all developing muscles as well as in human adult spinal cord motoneurons (Weterman et al., 2012) . It is involved in a variety of functions, including regulation of signaling pathways and cell adhesion, mediation of self-association, and involvement in cargo sorting during receptor endocytosis (Amit et al., 2004; McDonald and Martin-Serrano, 2008; Bian et al., 2017) . In our study, the mutation c. 2021 ) is located at the border of the highly conserved N-terminal RING finger motif region (amino acids 674-713) of the LRSAM1 protein.
As the activity of most E3 ubiquitin ligases has been reported to be specified by the RING domain (Deshaies and Joazeiro, 2009) , this mutation might affect the functional RING finger motif domain and most likely disturbs LRSAM1 E3 ligase activity. In fact, all the identified mutations alter the RING finger domain of LRSAM1 protein by either a frame shift, insertion of additional amino acids or missense mutation. However, the mechanisms by which each of these distinct LRSAM1 gene mutations causes the development of the sensory-motor axonal neuropathy still remains to be elucidated. The p.Leu708Argfx28 reduced the ubiquitin ligase activity of LRSAM1 protein in transfected cells. Injections of morpholino oligonucleotides in Zebrafish embryos to target the Lrsaml gene disturbed neurodevelopment, showing a less organized neural structure, abnormal tail formation, and affected movement and swimming behavior (Weterman et al., 2012) . LRSAM1 loss-of-function mutant mice show greater sensitivity and more rapid motor axon degeneration when challenged with the neurotoxic agent acrylamide (Bogdanik et al., 2013) . The p.Cys694Arg mutation leads to axonal degeneration in the culture neuronal cell line. The mutation disrupts the interactions between LRSAM1 and RNA-binding proteins and alters formation of nuclear transcription machinery (Hu et al., 2016) . LRSAM1 ubiquitylation activity was largely abrogated by the p.Leu708Argfs mutation, p.Pro707Leu mutation, and p.Cys694Tyr mutation (Hakonen et al., 2017) . Interestingly, it has been suggested that LRSAM1 may have a neuroprotective role against mutant huntingtin in Huntington's disease. Expression upregulation of LRSAM1 maybe lead to a delayed onset, prolonged disease progression, and longer lifespan of the disease. LRSAM1 maybe a promising, novel candidate disease modifier and maybe represent novel therapeutic avenues to decrease mutated huntingtin aggregate toxicity and cell death in Huntington's disease patients (Tang et al., 2011) .
